The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer

被引:3
|
作者
Kang, Yi-Kun [1 ]
Wang, Xue [1 ]
Hu, Nan-Lin [1 ]
Yue, Jian [1 ]
Si, Yi-Ran [1 ]
Ju, Jie [1 ]
Gao, Song-Lin [1 ]
Yuan, Peng [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept VIP Med Serv, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
中国国家自然科学基金;
关键词
endocrine therapy; lipid; breast cancer; premenopausal; ovarian function suppression; AROMATASE INHIBITORS; POSTMENOPAUSAL WOMEN; OVARIAN SUPPRESSION; TAMOXIFEN; ADJUVANT; EXEMESTANE; ESTROGEN; ANASTROZOLE; TOREMIFENE; RECEPTORS;
D O I
10.3389/fonc.2021.759595
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to evaluate and compare the effects of various endocrine therapies on lipid profiles in young patients with breast cancer. A retrospective, single-center study was performed to investigate the effects of tamoxifen (TAM), tamoxifen plus ovarian function suppression (TAM+OFS), and aromatase inhibitors plus ovarian function suppression (AI+OFS) on lipid profiles during the 60 months of endocrine therapy in hormone receptor-positive patients aged <40 with early breast cancer. The primary endpoint was the cumulative incidence of lipid events, and the secondary endpoints were the changes in lipid profiles. A total of 230 young patients were included with the mean age of 35.7 years old. The patients in TAM group had significantly lower incidence of 5-year lipid events than those in TAM+OFS group (7.4% versus 21.3%; P=0.016) and AI+OFS group (7.4% versus 21.6%; P=0.009). The incidence of fatty liver was significantly higher in TAM+OFS group than TAM group (52.5%versus 30.9%; P=0.043). Lipid events were associated with younger age (odds ratio (OR)=0.865, 95% confidence interval (CI): 0.780-0960; P=0.006), higher baseline LDL-C (OR=14.959, 95% CI: 4.379-51.105; P<0.001), and use of OFS (OR=3.557, 95% CI: 1.151-10.989; P=0.027). Therefore, application of OFS, with younger age and higher baseline LDL-C, may increase the incidence of lipid events in premenopausal breast cancer. More care should be taken for lipid profiles during the endocrine therapy for young breast cancer patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
    Wang, Kaiyue
    Shen, Lu
    Tian, Wei
    Zhang, Suzhan
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [2] Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
    Kaiyue Wang
    Lu Shen
    Wei Tian
    Suzhan Zhang
    [J]. Scientific Reports, 12
  • [3] Adjuvant endocrine therapies for postmenopausal women with early breast cancer: Standards and not
    Dellapasqua, S
    Castiglione-Gertsch, M
    [J]. BREAST, 2005, 14 (06): : 555 - 563
  • [4] Adjuvant therapies for very young women with early stage breast cancer
    Freedman, Rachel A.
    Partridge, Ann H.
    [J]. BREAST, 2011, 20 : S146 - S149
  • [5] Immune and endocrine effects of reflexology and massage in women with early breast cancer
    Green, V. L.
    Alexandropoulou, A.
    Walker, M. B.
    Walker, A. A.
    Sharp, D. M.
    Walker, L. G.
    Greenman, J.
    [J]. IMMUNOLOGY, 2008, 125 : 123 - 123
  • [6] Early breast cancer in very young women: the interphase between endocrine and chemotherapy treatment
    Francis, P.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 66 - 66
  • [7] Endocrine therapies of breast cancer
    Goldhirsch, A
    Gelber, RD
    [J]. SEMINARS IN ONCOLOGY, 1996, 23 (04) : 494 - 505
  • [8] The endocrine management of postmenopausal women with early breast cancer
    Michael Baum
    [J]. Breast Cancer, 2004, 11 (1) : 15 - 19
  • [9] Breast Conservation in Young Women With Early Breast Cancer
    Veronesi, U.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S71 - S72
  • [10] Endocrine therapy non-persistence and recurrence in young women with early stage breast cancer
    Rosenberg, Shoshana M.
    Zheng, Yue
    Poorvu, Philip
    Ruddy, Kathryn
    Gaither, Rachel
    Tamimi, Rulla
    Schapira, Lidia
    Peppercorn, Jeffrey
    Come, Steven
    Borges, Virginia
    Partridge, Ann
    [J]. CANCER RESEARCH, 2021, 81 (04)